Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.

Market Analysis and Insights: Global Prasugrel Hydrochloride Market
The global Prasugrel Hydrochloride market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.

Global Prasugrel Hydrochloride Scope and Market Size
The global Prasugrel Hydrochloride market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Prasugrel Hydrochloride market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
5mg
10mg

Segment by Application
Hospital
Drugs Store

The Prasugrel Hydrochloride market is analysed and market size information is provided by regions (countries). Segment by Application, the Prasugrel Hydrochloride market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
Daiichi Sankyo
Amneal Pharmaceuticals
Apotex
Ube
Ascend Laboratories
Liberty Pharmaceuticals
Panacea Biotec